Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers
Aims To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Methods Ten healthy volunteers were treated with clopidogrel (75 mg day−1) for 7 days. CD62P expression and PAC‐1 binding were measured by flow cytometry. Results Adenosine diphos...
Saved in:
| Published in | British journal of clinical pharmacology Vol. 52; no. 3; pp. 333 - 336 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Science Ltd
01.09.2001
Blackwell Science Blackwell Science Inc |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0306-5251 1365-2125 |
| DOI | 10.1046/j.0306-5251.2001.01453.x |
Cover
| Abstract | Aims To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.
Methods Ten healthy volunteers were treated with clopidogrel (75 mg day−1) for 7 days. CD62P expression and PAC‐1 binding were measured by flow cytometry.
Results Adenosine diphosphate (ADP, 30 µM)‐induced platelet responses were almost completely inhibited by clopidogrel. After discontinuation of the drug, platelet function gradually increased and complete recovery was seen 7 days after the last clopidogrel dose. The mean difference (95% CI) for ADP‐induced PAC‐1 binding (fluorescence intensity) between baseline and 7 days after the last dose was 0.01 (0.61, −0.59). Single cell analysis provides direct evidence for an irreversible mode of action of clopidogrel.
Conclusions This is the first report to directly demonstrate irreversibility of clopidogrel action in humans. |
|---|---|
| AbstractList | Aims To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.
Methods Ten healthy volunteers were treated with clopidogrel (75 mg day−1) for 7 days. CD62P expression and PAC‐1 binding were measured by flow cytometry.
Results Adenosine diphosphate (ADP, 30 µM)‐induced platelet responses were almost completely inhibited by clopidogrel. After discontinuation of the drug, platelet function gradually increased and complete recovery was seen 7 days after the last clopidogrel dose. The mean difference (95% CI) for ADP‐induced PAC‐1 binding (fluorescence intensity) between baseline and 7 days after the last dose was 0.01 (0.61, −0.59). Single cell analysis provides direct evidence for an irreversible mode of action of clopidogrel.
Conclusions This is the first report to directly demonstrate irreversibility of clopidogrel action in humans. Aims To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Methods Ten healthy volunteers were treated with clopidogrel (75 mg day −1 ) for 7 days. CD62P expression and PAC‐1 binding were measured by flow cytometry. Results Adenosine diphosphate (ADP, 30 µ M )‐induced platelet responses were almost completely inhibited by clopidogrel. After discontinuation of the drug, platelet function gradually increased and complete recovery was seen 7 days after the last clopidogrel dose. The mean difference (95% CI) for ADP‐induced PAC‐1 binding (fluorescence intensity) between baseline and 7 days after the last dose was 0.01 (0.61, −0.59). Single cell analysis provides direct evidence for an irreversible mode of action of clopidogrel. Conclusions This is the first report to directly demonstrate irreversibility of clopidogrel action in humans. To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Ten healthy volunteers were treated with clopidogrel (75 mg day(-1)) for 7 days. CD62P expression and PAC-1 binding were measured by flow cytometry. Adenosine diphosphate (ADP, 30 microM)-induced platelet responses were almost completely inhibited by clopidogrel. After discontinuation of the drug, platelet function gradually increased and complete recovery was seen 7 days after the last clopidogrel dose. The mean difference (95% CI) for ADP-induced PAC-1 binding (fluorescence intensity) between baseline and 7 days after the last dose was 0.01 (0.61, -0.59). Single cell analysis provides direct evidence for an irreversible mode of action of clopidogrel. This is the first report to directly demonstrate irreversibility of clopidogrel action in humans. To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.AIMSTo study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.Ten healthy volunteers were treated with clopidogrel (75 mg day(-1)) for 7 days. CD62P expression and PAC-1 binding were measured by flow cytometry.METHODSTen healthy volunteers were treated with clopidogrel (75 mg day(-1)) for 7 days. CD62P expression and PAC-1 binding were measured by flow cytometry.Adenosine diphosphate (ADP, 30 microM)-induced platelet responses were almost completely inhibited by clopidogrel. After discontinuation of the drug, platelet function gradually increased and complete recovery was seen 7 days after the last clopidogrel dose. The mean difference (95% CI) for ADP-induced PAC-1 binding (fluorescence intensity) between baseline and 7 days after the last dose was 0.01 (0.61, -0.59). Single cell analysis provides direct evidence for an irreversible mode of action of clopidogrel.RESULTSAdenosine diphosphate (ADP, 30 microM)-induced platelet responses were almost completely inhibited by clopidogrel. After discontinuation of the drug, platelet function gradually increased and complete recovery was seen 7 days after the last clopidogrel dose. The mean difference (95% CI) for ADP-induced PAC-1 binding (fluorescence intensity) between baseline and 7 days after the last dose was 0.01 (0.61, -0.59). Single cell analysis provides direct evidence for an irreversible mode of action of clopidogrel.This is the first report to directly demonstrate irreversibility of clopidogrel action in humans.CONCLUSIONSThis is the first report to directly demonstrate irreversibility of clopidogrel action in humans. |
| Author | Hohlfeld, Thomas Schrör, Karsten Weber, Artur‐Aron Braun, Marina Schwippert, Barbara Tschöpe, Diethelm |
| Author_xml | – sequence: 1 givenname: Artur‐Aron surname: Weber fullname: Weber, Artur‐Aron – sequence: 2 givenname: Marina surname: Braun fullname: Braun, Marina – sequence: 3 givenname: Thomas surname: Hohlfeld fullname: Hohlfeld, Thomas – sequence: 4 givenname: Barbara surname: Schwippert fullname: Schwippert, Barbara – sequence: 5 givenname: Diethelm surname: Tschöpe fullname: Tschöpe, Diethelm – sequence: 6 givenname: Karsten surname: Schrör fullname: Schrör, Karsten |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1106021$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11560568$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkVFvFCEQx4mpsdfqVzA8GN92BXbhdh800YutTZrUGH0mLDvb48LBCezZ-_ay1-tZfbHwwAR-859h_mfoxHkHCGFKSkpq8W5VkoqIgjNOS0YILQmteVXePUMzWgleMMr4CZodoVN0FuMqgxUV_AU6pZQLwkUzQ9030H4LYYf9gDdWJbCQ8DA6nYx3WA0JAu5N1N4l40a1v82otn5jen8bwOIUQKU1uISNw0tQNi13eOvt6BJAiC_R80HZCK8O5zn6cfH5--JLcX1zebX4eF1oLnhVUD7UuiKN5r3WHWnartMAnWCqbuc1zKGvWC_Y0OYlWtVqRUGTXhAA3XVNX52jD_e6m7FbQ69zQ0FZuQlmrcJOemXk3y_OLOWt30o2Ta-mWeDtQSD4nyPEJNf542CtcuDHKOeUNnmLDL5-XOlY4mGsGXhzAFTUyg5BOW3iI44IwuifjnXwMQYYpDZpP-Lcn7GSEjnZLVdyclJOTsrJbrm3W95lgeYfgWOJ_6e-v0_9ZSzsnpwnPy2-TlH1G03HxZA |
| CODEN | BCPHBM |
| CitedBy_id | crossref_primary_10_23736_S1824_4777_22_01550_9 crossref_primary_10_1089_end_2010_0355 crossref_primary_10_1186_s12891_016_0988_9 crossref_primary_10_1016_j_jacc_2009_09_038 crossref_primary_10_1177_000313480907501009 crossref_primary_10_1016_j_amjcard_2009_06_015 crossref_primary_10_1016_j_carrev_2022_08_005 crossref_primary_10_1016_j_amjmed_2011_07_038 crossref_primary_10_1053_j_trap_2006_04_002 crossref_primary_10_1136_jnis_2009_001859 crossref_primary_10_2165_00003088_200443140_00002 crossref_primary_10_1093_bja_aem089 crossref_primary_10_1016_j_injury_2024_111924 crossref_primary_10_1016_j_athoracsur_2011_07_071 crossref_primary_10_1097_BOT_0b013e3181c3f3d9 crossref_primary_10_1097_MBC_0000000000000625 crossref_primary_10_1007_s40256_013_0059_7 crossref_primary_10_2500_ajr_2007_21_3019 crossref_primary_10_1016_j_amjcard_2008_02_109 crossref_primary_10_1007_s00059_012_3593_1 crossref_primary_10_1093_bja_ael318 crossref_primary_10_1016_j_clim_2012_09_004 crossref_primary_10_1097_CM9_0000000000001668 crossref_primary_10_1007_s00392_011_0310_7 crossref_primary_10_5435_JAAOS_D_16_00184 crossref_primary_10_1007_s00701_011_0968_7 crossref_primary_10_1016_j_pharmthera_2009_03_019 crossref_primary_10_1517_14656566_6_5_755 crossref_primary_10_1111_j_1538_7836_2007_02800_x crossref_primary_10_12968_hmed_2008_69_1_28046 crossref_primary_10_1016_j_injury_2007_01_011 crossref_primary_10_1097_NRL_0b013e31815a393e crossref_primary_10_1111_j_1538_7836_2009_03716_x crossref_primary_10_1517_17425255_3_4_621 crossref_primary_10_1159_000097664 crossref_primary_10_4055_jkoa_2015_50_3_192 crossref_primary_10_2460_ajvr_71_7_822 crossref_primary_10_2106_JBJS_RVW_N_00105 crossref_primary_10_1016_j_wneu_2011_02_010 crossref_primary_10_1016_j_crad_2018_05_009 crossref_primary_10_1017_S0022215112001545 crossref_primary_10_1046_j_1365_2044_2003_02960_x crossref_primary_10_1177_230949901302100205 crossref_primary_10_1007_s00068_008_8093_x crossref_primary_10_1007_s10195_013_0235_1 crossref_primary_10_1016_j_athoracsur_2005_03_074 crossref_primary_10_1016_j_rcot_2016_10_105 crossref_primary_10_1016_j_bjmsu_2010_08_004 crossref_primary_10_1186_cc11292 crossref_primary_10_2217_14796678_1_5_579 crossref_primary_10_1016_j_ccell_2011_08_012 crossref_primary_10_1016_j_arth_2017_01_048 crossref_primary_10_4103_0019_5049_60510 crossref_primary_10_1097_EJA_0b013e32832eb521 crossref_primary_10_47795_STKK4952 crossref_primary_10_1007_s12265_013_9517_5 crossref_primary_10_1016_j_bpa_2007_02_002 crossref_primary_10_1371_journal_pone_0106239 crossref_primary_10_5371_hp_2015_27_3_173 crossref_primary_10_1161_JAHA_117_007288 crossref_primary_10_1517_14656566_2012_642862 crossref_primary_10_1016_j_amjcard_2020_06_066 crossref_primary_10_1038_nrurol_2011_106 crossref_primary_10_1097_TA_0b013e31828cca61 crossref_primary_10_1161_01_CIR_0000081770_51929_5A crossref_primary_10_1007_s11033_014_3613_8 crossref_primary_10_1308_003588409X391820 crossref_primary_10_1016_j_jacc_2008_08_031 crossref_primary_10_1016_j_otsr_2016_08_022 crossref_primary_10_1016_j_spinee_2010_10_013 crossref_primary_10_1016_j_ijscr_2021_106589 crossref_primary_10_7759_cureus_43899 crossref_primary_10_12671_jkfs_2012_25_2_105 crossref_primary_10_1016_j_ancv_2015_12_008 crossref_primary_10_4236_health_2013_510233 crossref_primary_10_7759_cureus_37890 crossref_primary_10_1253_circj_CJ_11_0620 crossref_primary_10_1016_j_ijcard_2008_10_050 crossref_primary_10_1093_bja_aer298 crossref_primary_10_1111_j_1365_2362_2005_01522_x crossref_primary_10_1517_13543780903176415 crossref_primary_10_1093_eurheartj_ehp296 crossref_primary_10_1016_j_cca_2009_03_055 crossref_primary_10_1016_j_phrs_2021_105547 crossref_primary_10_4137_CMT_S2334 crossref_primary_10_1097_BOT_0b013e318257d1b7 crossref_primary_10_3390_jcm11216570 crossref_primary_10_1111_j_1399_6576_2009_02089_x crossref_primary_10_1016_j_ccl_2007_12_007 crossref_primary_10_1016_j_ijscr_2021_106578 crossref_primary_10_1186_1477_9560_12_10 crossref_primary_10_1093_bja_aem209 crossref_primary_10_1016_j_adaj_2015_01_002 crossref_primary_10_1016_j_rmcr_2022_101782 crossref_primary_10_1007_s12928_020_00642_w crossref_primary_10_1016_j_injury_2012_11_028 crossref_primary_10_1016_j_cger_2005_09_002 crossref_primary_10_1111_bjh_12107 crossref_primary_10_1007_s12471_011_0197_y crossref_primary_10_1016_j_injury_2015_03_024 crossref_primary_10_1097_01586154_201305000_00027 crossref_primary_10_1097_SLA_0000000000001726 crossref_primary_10_1007_s12471_023_01825_9 crossref_primary_10_1093_bja_aep373 crossref_primary_10_1097_01_bot_0000415065_40886_ae crossref_primary_10_1111_j_1445_2197_2009_04981_x crossref_primary_10_2217_fca_2016_0028 crossref_primary_10_1016_S0002_8703_03_00260_6 crossref_primary_10_1002_ccd_23172 crossref_primary_10_1016_j_jsurg_2006_10_003 crossref_primary_10_1161_01_ATV_0000092127_16125_E6 crossref_primary_10_1016_j_athoracsur_2024_07_013 crossref_primary_10_1097_IOP_0b013e31827f599e crossref_primary_10_1016_j_injury_2019_09_011 crossref_primary_10_1093_bja_aer288 crossref_primary_10_1016_j_arth_2018_09_065 crossref_primary_10_1590_0004_282x20190066 crossref_primary_10_1016_j_itjm_2010_05_009 crossref_primary_10_1016_j_athoracsur_2004_09_058 |
| Cites_doi | 10.1038/sj.bjp.0702276 10.1016/S0140-6736(00)02175-9 10.1055/s-0037-1614651 10.1161/01.CIR.100.15.1667 10.1055/s-0037-1614133 10.1055/s-0037-1615088 10.1161/01.ATV.19.8.2007 10.1007/978-3-642-60639-7_27 10.2165/00003495-199754050-00006 |
| ContentType | Journal Article |
| Copyright | 2001 INIST-CNRS 2001 Blackwell Science Ltd 2001 |
| Copyright_xml | – notice: 2001 INIST-CNRS – notice: 2001 Blackwell Science Ltd 2001 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1046/j.0306-5251.2001.01453.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1365-2125 |
| EndPage | 336 |
| ExternalDocumentID | PMC2014541 11560568 1106021 10_1046_j_0306_5251_2001_01453_x BCP1453 |
| Genre | shortCommunication Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5653-15f4c308c5dccb089bbceeb62a4974e7ed32d62f999969a9ca1ec0d60eecbb8d3 |
| IEDL.DBID | DR2 |
| ISSN | 0306-5251 |
| IngestDate | Thu Aug 21 14:14:18 EDT 2025 Fri Jul 11 03:45:48 EDT 2025 Wed Feb 19 02:33:32 EST 2025 Mon Jul 21 09:12:07 EDT 2025 Tue Jul 01 02:29:12 EDT 2025 Thu Apr 24 23:11:27 EDT 2025 Wed Jan 22 17:02:15 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Human Platelet Healthy subject Treatment withdrawal Clopidogrel ADP Biological activity Antiplatelet agent Duration of action |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5653-15f4c308c5dccb089bbceeb62a4974e7ed32d62f999969a9ca1ec0d60eecbb8d3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.0306-5251.2001.01453.x |
| PMID | 11560568 |
| PQID | 71181816 |
| PQPubID | 23479 |
| PageCount | 4 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2014541 proquest_miscellaneous_71181816 pubmed_primary_11560568 pascalfrancis_primary_1106021 crossref_citationtrail_10_1046_j_0306_5251_2001_01453_x crossref_primary_10_1046_j_0306_5251_2001_01453_x wiley_primary_10_1046_j_0306_5251_2001_01453_x_BCP1453 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | September 2001 |
| PublicationDateYYYYMMDD | 2001-09-01 |
| PublicationDate_xml | – month: 09 year: 2001 text: September 2001 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: London – name: England |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 2001 |
| Publisher | Blackwell Science Ltd Blackwell Science Blackwell Science Inc |
| Publisher_xml | – name: Blackwell Science Ltd – name: Blackwell Science – name: Blackwell Science Inc |
| References | 2000; 84 1997 1999; 100 1999; 82 2000; 355 1997; 54 1999; 19 1999; 126 1999; 25 1998; 79 e_1_2_6_8_2 Herbert J‐M (e_1_2_6_5_2) 1999; 82 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_12_2 e_1_2_6_2_2 e_1_2_6_10_2 Lins R (e_1_2_6_11_2) 1999; 25 Thebault J‐J (e_1_2_6_7_2) 1999; 25 |
| References_xml | – volume: 84 start-page: 891 year: 2000 end-page: 896 article-title: Identification and biological activity of the active metabolite of clopidogrel publication-title: Thromb Haemost – volume: 25 start-page: 29 issue: Suppl 2 year: 1999 end-page: 33 article-title: Pharmacokinetic profile of 14C‐labeled clopidogrel publication-title: Sem Thromb Hemost – volume: 126 start-page: 415 year: 1999 end-page: 420 article-title: Specific inhibition of ADP‐induced platelet aggregation by clopidogrel publication-title: Br J Pharmacol – volume: 82 start-page: 156 year: 1999 end-page: 157 article-title: Savi P. Non‐specific inhibition of ADP‐induced platelet antiaggregation by clopidogrel in vitro publication-title: Thromb Haemost – volume: 79 start-page: 885 year: 1998 end-page: 896 article-title: European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function publication-title: Thromb Haemost – volume: 25 start-page: 9 issue: Suppl 2 year: 1999 end-page: 14 article-title: Repeated dose pharmacodynamics of clopidogrel in healthy subjects publication-title: Sem Thromb Hemost – start-page: 619 year: 1997 end-page: 643 – volume: 54 start-page: 745 year: 1997 end-page: 750 article-title: Clopidogrel publication-title: Drugs – volume: 100 start-page: 1667 year: 1999 end-page: 1672 article-title: Ticlopidine and clopidogrel publication-title: Circulation – volume: 355 start-page: 1531 year: 2000 end-page: 1539 article-title: Platelets publication-title: Lancet – volume: 19 start-page: 2007 year: 1999 end-page: 2011 article-title: Specific impairment of human platelet P2Y ADP receptor‐mediated signaling by the antiplatelet drug clopidogrel publication-title: Arterioscler Thromb Vasc Biol – ident: e_1_2_6_4_2 doi: 10.1038/sj.bjp.0702276 – ident: e_1_2_6_12_2 doi: 10.1016/S0140-6736(00)02175-9 – volume: 82 start-page: 156 year: 1999 ident: e_1_2_6_5_2 article-title: Savi P. Non‐specific inhibition of ADP‐induced platelet antiaggregation by clopidogrel in vitro publication-title: Thromb Haemost doi: 10.1055/s-0037-1614651 – ident: e_1_2_6_3_2 doi: 10.1161/01.CIR.100.15.1667 – ident: e_1_2_6_6_2 doi: 10.1055/s-0037-1614133 – volume: 25 start-page: 9 issue: 2 year: 1999 ident: e_1_2_6_7_2 article-title: Repeated dose pharmacodynamics of clopidogrel in healthy subjects publication-title: Sem Thromb Hemost – ident: e_1_2_6_8_2 doi: 10.1055/s-0037-1615088 – ident: e_1_2_6_2_2 doi: 10.1161/01.ATV.19.8.2007 – ident: e_1_2_6_9_2 doi: 10.1007/978-3-642-60639-7_27 – volume: 25 start-page: 29 issue: 2 year: 1999 ident: e_1_2_6_11_2 article-title: Pharmacokinetic profile of 14C‐labeled clopidogrel publication-title: Sem Thromb Hemost – ident: e_1_2_6_10_2 doi: 10.2165/00003495-199754050-00006 |
| SSID | ssj0013165 |
| Score | 2.0838802 |
| Snippet | Aims To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.
Methods Ten healthy volunteers were... Aims To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Methods Ten healthy volunteers were... To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Ten healthy volunteers were treated with... To study the recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.AIMSTo study the recovery of platelet function... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 333 |
| SubjectTerms | Adenosine Diphosphate - pharmacology Adult Binding, Competitive - drug effects Biological and medical sciences Blood Platelets - drug effects Blood Platelets - metabolism Blood Platelets - physiology Blood. Blood coagulation. Reticuloendothelial system Clopidogrel Flow Cytometry Humans irreversibility Male Medical sciences P-Selectin - drug effects P-Selectin - metabolism Pharmacology. Drug treatments Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - pharmacology platelets Short Reports Ticlopidine - analogs & derivatives Ticlopidine - pharmacology Time Factors |
| Title | Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1046%2Fj.0306-5251.2001.01453.x https://www.ncbi.nlm.nih.gov/pubmed/11560568 https://www.proquest.com/docview/71181816 https://pubmed.ncbi.nlm.nih.gov/PMC2014541 |
| Volume | 52 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT-MwELYQp5UQsMury7LrA-JEojiJneTI8hQSqEIg9RbZjgMsVVLRVqL8embsNKXAAa24VJGaaevJjOebeuYbQnZVkXET8MIrS556sEtGXqqCxFM8TEQsBaBU7He-uBRnN_F5j_ea-ifshXH8EO0fbugZdr9GB5fKTSEJLLvtPx_hLiRS3KZ5zMcDsshHPMkigTT6R1fh7ECB2amSrUhT1OMOOD_-oLlItTSQQ1Ba6aZdfARH31dVvka7NlydrJCH6UJdlcqDPx4pXz-_4YD8Gk2skuUG1dIDZ4bfyYKpfpC9rqPFnuzT61mX13Cf7tHujDB7skYU5sDgUhNal3TQB_QLxkQx4qLVUDvGnGL7cI1jLRw3Od6qsdurqG8fTZ-2BfP0vqKuuXNCcesFwwGEu05uTo6vD8-8ZvaDpwFiRh7jZayjINW80FoFaaYUhHMlQhlDBmQSU0RhIcIyw4Qtk5mWzOigEIExWqm0iDbIYlVXZovQMkFeOthNsQ-YxUYpKVWYJJkE8AZxokOS6XPOdUOMjvM5-rk9oI-xmQ0VnKOCcWwny62C86cOYa3kwJGDfEJmZ86UZoKQnAPg6pA_U9PKwdPx-EZWph4P8wR7hFMmOmTTGdorUcCtXKSwkjkTbG9ADvH5d6r7O8slHuLPiuFbhbWwTy8j_3vYxauf_yu4Tb65cj4s1_tFFkePY7MD-G6kflvPhdfTHnsBrnhE0w |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEB6hcgAJlfIO9LEH1FMd_Nq1fYRCFaCtIpRKva121-tSEdlRk0gNv56ZXcdpaA8V4hbJnjg7mdn9xjPzDcB7XRbchrwMqornAe6SSZDrMAs0jzORKoEolfqdT07F4Cz9ds7P23FA1Avj-SG6F27kGW6_JgenF9If2rSk83LCuxhJcRfnRX3KkCV9BJQPU8QdFIl9_hGvUgqRmyvZybRlPT7Fefc3rZ1VTyZqimqr_LyLuwDp7brKm3jXHVhHT2G8XKqvU_nVn8903_z-iwXyP-liCzZbYMs-ekt8Bg9s_Rz2h54Ze3HARqtGr-kB22fDFWf24gVoCoPRqxasqdhkjAAY7YnRoUuGw9wkc0YdxA1NtvD05HSroYavsrm4smPW1cyzy5r5_s4Fo90XbQdB7ks4O_oyOhwE7fiHwCDKTIKIV6lJwtzw0hgd5oXWeKJrEasUgyCb2TKJSxFXBcVshSqMiqwJSxFaa7TOy-QVbNRNbd8AqzKipsMNlVqBo9RqrZSOs6xQiN_wqOhBtvyjpWm50WlEx1i6HH1K_WykYEkKpsmdkXQKltc9iDrJiecHuYfMzpotrQQxPkfM1YO9pW1JdHbK4KjaNvOpzKhNOI9ED157S7shitCVixxXsmaD3Q1EI75-pb786ejEY_pZKT5VOBO79zLkp8MhfXr7r4J78GgwOjmWx19Pv7-Dx766j6r3tmFjdjW3Owj3ZnrXufEfRd9IAQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEB6hIiEkVN4QoHQPqKc6-LVr-wiFqLyqCLVSb6t9GapGdtQkUsOvZ2bXcRrooULcItkTZyczu994Zr4BeKNtxV3MbVTXvIxwl8yiUsdFpHlaiFwJRKnU7_ztSBye5J9P-WlX_0S9MIEfon_hRp7h92ty8Kmt33ZZSe_kBHcxkOI-zEuGlCDLhognb-cCgQUBpO_pOqOQ-LGSvUxX1RMynNd_08ZRdW-qZqi1Ooy7uA6P_l1WeRXu-vNqdB_OVysNZSrnw8VcD82vP0gg_48qHsB2B2vZu2CHD-GWax7B3jjwYi_32fG6zWu2z_bYeM2YvXwMmoJg9Kkla2s2nSD8RWtidOSS2TA_x5xR_3BLcy0COTndaqjdy7Y_LtyE9RXz7KxhobtzyWjvRctBiPsETkYfjw8Oo274Q2QQY2ZRwuvcZHFpuDVGx2WlNZ7nWqQqxxDIFc5mqRVpXVHEVqnKqMSZ2IrYOaN1abOnsNW0jXsOrC6ImA63U2oETnKntVI6LYpKIXrDg2IAxep_lqZjRqcBHRPpM_Q5dbORgiUpmOZ2JtIrWF4OIOklp4Ed5AYyOxumtBbE6BwR1wB2V6Yl0dUpf6Ma1y5msqAm4TIRA3gWDO2KKAJXLkpcyYYJ9jcQifjmlebspycTT-ln5fhU4S3sxsuQ7w_G9OnFvwruwp3xh5H8-unoy0u4G0r7qHTvFWzNLxZuB7HeXL_2TvwbLNlGsA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recovery+of+platelet+function+after+discontinuation+of+clopidogrel+treatment+in+healthy+volunteers&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Weber%2C+Artur-Aron&rft.au=Braun%2C+Marina&rft.au=Hohlfeld%2C+Thomas&rft.au=Schwippert%2C+Barbara&rft.date=2001-09-01&rft.pub=Blackwell+Science+Inc&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=52&rft.issue=3&rft.spage=333&rft.epage=336&rft_id=info:doi/10.1046%2Fj.0306-5251.2001.01453.x&rft_id=info%3Apmid%2F11560568&rft.externalDocID=PMC2014541 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |